Business, energy, technology, markets and global industry news from Business News Today

SANRECO

PharmaDeviceNews SANRECO
Silence Therapeutics’ $175 million public offering strengthens its funding position as divesiran advances toward planned Phase 3 development in polycythemia vera. Representative image.
Pharma & Biotech

Merck is paying a 130% premium for Silence Therapeutics. Is divesiran the main prize?

Merck KGaA has agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, offering $20 per ADS. The transaction centers on divesiran, an RNA interference therapy that achieved an 88% response rate in Phase 2 polycythemia vera testing.

Read More
Silence Therapeutics’ $175 million public offering strengthens its funding position as divesiran advances toward planned Phase 3 development in polycythemia vera. Representative image.
Pharma & Biotech

Silence Therapeutics raised $175m right after SANRECO success. What does it unlock for divesiran?

Silence Therapeutics raises $175 million after positive divesiran Phase 2 data, strengthening funding ahead of a planned Phase 3 PV trial.

Read More
Silence Therapeutics approaches a key Phase 2 SANRECO trial readout for divesiran in polycythemia vera, with investors and clinicians watching hematocrit control, phlebotomy reduction and the potential of infrequent RNA interference therapy. Representative image.
Pharma & Biotech

What will Silence Therapeutics’ SANRECO Phase 2 results reveal about divesiran in polycythemia vera?

Silence Therapeutics will reveal Phase 2 SANRECO divesiran results in polycythemia vera, testing hematocrit control and phlebotomy reduction.

Read More